VIVOS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.15 USD | +25.10% |
|
+41.51% | +107.47% |
| Sales 2022 | 0.04 3.05 | Sales 2023 | 0.02 1.63 | Capitalization | 27.78M 2.32B |
|---|---|---|---|---|---|
| Net income 2022 | -2M -167M | Net income 2023 | -2M -167M | EV / Sales 2022 | 39,28,64,544 x |
| Net cash position 2022 | 1.71M 142M | Net cash position 2023 | 1.59M 133M | EV / Sales 2023 | 1,34,29,60,256 x |
| P/E ratio 2022 |
-6.32
x | P/E ratio 2023 |
-9.21
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +25.10% | ||
| 1 week | +41.51% | ||
| Current month | +107.47% | ||
| 1 month | +107.47% | ||
| 3 months | +135.48% | ||
| 6 months | +154.24% | ||
| Current year | +107.47% |
1 week
0.10
0.16
1 month
0.070.16
Current year
0.050.16
1 year
0.040.16
3 years
0.040.16
5 years
0.010.31
10 years
0.0132.80
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Korenko
CEO | Chief Executive Officer | 77 | 01/16/01 |
Carlton Cadwell
CHM | Chairman | 79 | 01/06/01 |
Michael Pollack
DFI | Director of Finance/CFO | 57 | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carlton Cadwell
CHM | Chairman | 79 | 01/06/01 |
Michael Korenko
CEO | Chief Executive Officer | 77 | 01/16/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.15 | +25.10% | 2,763,974 |
| 25/24/25 | 0.1199 | +0.97% | 1,061,702 |
| 24/24/24 | 0.1188 | +13.10% | 1,558,667 |
| 23/24/23 | 0.105 | -1.41% | 230,748 |
| 22/24/22 | 0.1065 | +0.47% | 399,559 |
Delayed Quote OTC Markets, April 27, 2024 at 01:29 am IST
More quotes
Vivos Inc. is a radiation oncology medical device company. The Company is engaged in the development of its yttrium-90 (Y-90) based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. RadioGel is a device for human therapy for non-resectable cancers in humans. It is a hydrogel liquid containing tiny Yttrium-90 phosphate microparticles that may be administered directly into a tumor. The Companyâs IsoPet division is focused on bringing RadioGel yttrium-90 precision radionuclide therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors. The IsoPet solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The Company is also engaged in developing a micro-injection system for small tumor therapy for treating cancerous thyroid lymph nodes.
| 1st Jan change | Capi. | |
|---|---|---|
| +107.47% | 58.48M | |
| -5.77% | 14.6B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +11.68% | 239M | |
| +1.67% | 183M | |
| -.--% | 168M |
- Stock Market
- Equities
- RDGL Stock
